PPSS Group Launch Next Generation Body Armour Offering Previously Unthinkable Levels Of Protection
4.12.2019 16:30:00 EET | Business Wire | Press release
PPSS Group's next generation of high-performance body armour is taking personal protection to a completely new-found level.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005491/en/
PPSS Group using carbon fibre composites technology for their latest development (Photo: Business Wire)
Thoroughly field tested, the body armour will be made available from Monday 06 January 2020. A demonstration of the body armour is available to view here.
Made from Auxilam™, a unique carbon fibre composite material, this latest body armour will protect the wearer from even the most vicious and brutal types of edged weapon and shanks imaginable.
Utilising a combination of the incredible strength of carbon fibre, the auxetic properties of Auxilam™ technology and some additional ‘top secret’ assets derived from the specially developed composite structure, this next generation of body armour offers a truly outstanding balance of weight, protection, performance and durability.
Comparing it with PPSS Group’s highly acclaimed polycarbonate-based stab resistant vests, the company is claiming a reduction of 19% in thickness (utilising a 3.9mm carbon fibre composite) and a 6.6% lower aerial density and reduced weight for its latest development.
Yet, it will be certified to KR2/SP2 according to the UK Home Office Body Armour Standard, as well as NIJ Level 2 (Stab & Spike) and VPAM K2/D2 meaning it will offer a truly significant higher level of knife, spike and needle protection.
Government agencies and security companies will be able to chose from an array of different styles, ranging from covert, overt to hi viz overt options.
Robert Kaiser, CEO of PPSS Group states: “Law Enforcement, Border Force, Immigration, Customs and Prison Officers are being attacked by criminals carrying and using knives, machetes, shanks, blunt objects and hypodermic needles every day.”
“Our key objective is to protect those men and women even more effectively. Using the very latest in technology and following extensive research and development, our latest body armour is now offering previously absolutely unthinkable levels of protection.”
“It also offers exceptional, VPAM certified protection from blunt objects, effectively reducing the risks of blunt force trauma injuries e.g. internal bleeding.”
The UK headquartered firm has been supplying countless of homeland security agencies in countries around the world with their widely respected polycarbonate-based stab resistant vests over the past ten years.
Please contact PPSS Group directly in case you have any questions in regards to this press release.
About PPSS Group:
PPSS Group is specialised in the development, manufacturing and supply of high-performance personal protective equipment, offering unrivalled protection from edged weapons, blunt force trauma and even human bites. PPSS Group’s social media presence: Facebook, LinkedIn, Twitter, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005491/en/
Contact information
Media Contact:
Ryan Vickers – Chief Development Officer (CDO)
E: info@ppss-group.com
T: +44 (0) 845 5193953
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom